Table 1. The baseline clinical characteristics of patients.
| Overall (n = 44) | Cilostazol (+) (n = 22) | Cilostazol (−) (n = 22) | P value | |
|---|---|---|---|---|
| Age, years | 67 ± 8 | 67 ± 7 | 66 ± 10 | 0.81 |
| Male, n (%) | 34 (77.3%) | 16 (72.7%) | 18 (81.8%) | 0.47 |
| Hypertension, n (%) | 32 (72.7%) | 18 (81.8%) | 14 (63.6%) | 0.18 |
| Hyperlipidemia, n (%) | 38 (86.4%) | 19 (86.4%) | 19 (86.4%) | 1.00 |
| Diabetes, n (%) | 19 (43.2%) | 10 (45.5%) | 9 (40.9%) | 0.76 |
| CKD, n (%) | 5 (11.4%) | 1 (4.6%) | 4 (18.1%) | 0.15 |
| Current Smoker, n (%) | 13 (29.6%) | 5 (22.7%) | 8 (36.3%) | 0.32 |
| CVD, n (%) | 2 (4.6%) | 0 | 2 (9.1%) | 0.15 |
| PAD, n (%) | 1 (2.3%) | 0 | 1 (4.6%) | 0.31 |
| Previous MI | 10 (22.7%) | 5 (22.7%) | 5 (22.7%) | 1.00 |
| UAP, n (%) | 16 (38.4%) | 6 (37.5%) | 10 (45.5%) | 0.21 |
| Medication, n (%) | ||||
| ACE-I/ARB | 26 (59.1%) | 14 (63.6%) | 12 (54.6%) | 0.54 |
| β-blokers | 13 (29.6%) | 4 (18.2%) | 9 (40.9%) | 0.10 |
| CCB | 19 (43.2%) | 11 (50.0%) | 8 (36.4%) | 0.36 |
| Statin | 40 (90.9%) | 19 (86.4%) | 21 (95.5%) | 0.29 |
| Nitrate/Nicorandil | 7 (15.9%) | 5 (22.7%) | 2 (9.1%) | 0.22 |
The data are shown as the mean ± SD or n (%). CKD, chronic kidney disease; CVD, cerebrovascular disease; PAD, peripheral artery disease; Previous MI, previous myocardial infarction; EF, ejection fraction; UAP, unstable angina pectoris; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium-channel blocker.